Phase 3 Stroke Trial, Recruiting NCT07509645 Sponsor: Capital Medical University Condition: Stroke
Back to Stroke

Phase 3 Stroke Trial, Recruiting

NCT07509645
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years old or older, of any sex
  • You have had an acute stroke caused by a blocked basilar artery (a major artery at the base of the brain)
  • You and your care team have decided to go ahead with an emergency procedure to open the blocked artery (endovascular treatment)
  • The time between your stroke starting and the start of the procedure is within 24 hours
  • Your stroke symptoms are rated as moderately severe or severe based on a standard medical stroke scoring tool (score of 10 or higher on the NIHSS)
  • A brain scan shows that the damage to the back part of your brain is not too extensive (score of 6 or higher on a specific CT scan scoring system)
  • You, or someone legally authorised to act on your behalf, have signed a consent form to participate

Who may not be able to join:

  • You have any type of bleeding in or around the brain (such as a brain bleed or bleeding around the brain's surface)
  • You had significant disability before this stroke (confirm with trial site)
  • You have a known allergy to the study drug tocilizumab or any of its ingredients
  • You have a known allergy to the dye used in imaging scans (iodinated contrast agents)
  • Your blood vessels are too twisted or curved to safely complete the artery-opening procedure (confirm with trial site)
  • You have a history of bleeding disorders, problems with blood clotting, or conditions involving low platelet counts
  • Your blood pressure remains very high (systolic 180 mmHg or above, or diastolic 110 mmHg or above) even after attempts to lower it
  • Your white blood cell count (specifically neutrophils) is too low, based on a blood test
  • Your platelet count (cells that help blood clot) is too low, based on a blood test
  • Your blood sugar level is either too low or too high at the time of the trial
  • Your liver enzyme levels (ALT or AST) are more than twice the normal upper limit, based on a blood test
  • Your kidney function is significantly reduced, based on blood tests
  • You are pregnant, breastfeeding, or planning to become pregnant within 90 days
  • You have a severe mental health condition or dementia that would prevent you from giving consent or attending follow-up appointments
  • You have an active cancer or a serious illness where life expectancy is less than 90 days
  • You have an autoimmune disease or are currently taking medicines that suppress the immune system
  • You have an active infection affecting your whole body
  • You have taken part in another interventional clinical trial in the last 30 days, or are currently in one
  • The trial doctors have any other concern that joining the trial could be harmful to you
  • The trial doctors feel there is any other reason that might prevent you from fully participating or following the study requirements (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 2 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Capital Medical University
Registry
ClinicalTrials.gov
Start date
22 April 2026
Est. completion
20 April 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Proportion of patients with a modified Rankin Scale (mRS) score of 0-3 at 90 days.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov